Page 62 - Ruchika Chitravanshi/workspace/business Standard Web/undefined

PM Modi meet with CMs to kickstart mega Covid-19 vaccination drive

The government is in the final stages of due diligence to ink a supply deal with Serum Institute of India and Bharat Biotech, which have got approval for emergency use of their vaccines

MCA proposes pre-packaged insolvency resolution process for Covid defaults

The future phases would cover a default above Rs 1 crore, followed by Rs 1 to Rs 1 lakh

Dry run for Covid-19 vaccine: States raise software, broadband issues

On Thursday, Health Minister Harsh Vardhan held a virtual meeting with the health ministers of all states on preparation and protocol for the Friday dry run

Around 75% of elderly in India suffering from a chronic disease: Study

The survey found that more than one in 10 people aged 60 and above have 'probable major depression' in states including Madhya Pradesh, Uttar Pradesh, Delhi, Bihar and Goa

Govt clears air on Bharat Biotech's vaccine, says relied on safety data

Minutes of expert panel meeting made public

Covid-19 vaccine: I am not worried about the efficacy, says Jacob John

I would go for Bharat Biotech's Covaxin and not Covishield, and that is my personal judgment, the former head of Centre for Advanced Research in Virology at ICMR says

Serum, Bharat Biotech vaccines get restricted use approval from DCGI

While the Oxford-AstraZeneca vaccine made by Serum Institute here has 70.42% efficacy, Bharat Biotech's still does not have efficacy data as trials are underway in India

Controversy around Bharat Biotech's Covaxin approval without efficacy data

Bharat Biotech's Covaxin is based on a whole inactivated virus platform, an old technology which is used to make vaccines given to infants

India readies for mega Covid vaccine rollout; phase 1 targets 300 million

On priority list: Health care and frontline workers; those over 50; and below 50 with co-morbidities

Covid vaccination voluntary, those already infected can also get the jab

A detailed FAQ released by health ministry has also addressed issues on suitability in co-morbid cases, delivery procedure among other things

COVAX gains access to 2 billion doses of vaccines for 190 member economies

First deliveries are expected to begin in the first quarter of 2021 depending upon regulatory approvals and readiness of countries for delivery

Health sector wants higher outlay, universal insurance in upcoming Budget

Govt officials say health outlay will have to rise significantly not just for vaccine expense but also for creation of supporting infra and distribution channels

Barely a week before the deadline, IBC resumption hangs in balance

The official said that while on the one hand green shoots were visible in the economy and the stock market was booming, on the other things were not moving under IBC

Vial, syringe makers push the pedal as Covid-19 vaccine roll-out nears

Most firms plan to increase capacity to meet fresh orders

More than 60% of insolvency proceedings led to liquidation in Sep quarter

Liquidations were only one-third of total cases closed in the previous quarter

States told to estimate and strengthen cold chain for vaccine: Health secy

In all, 29,000 cold chain points, 240 walk-in coolers, 70 walk-in freezers, 45,000 ice-lined refrigerators, 41,000 deep freezers and 300 solar refrigerators are to be used

AIIMS director appeals to nurses to end strike, assures pay hike resolution

Randeep Guleria says most of the union's 23 demands had been met, save perceived anomaly on initial pay under sixth pay commission, adding that govt has agreed to view this sympathetically

No pressure on regulator to approve a vaccine, says NITI Aayog's V K Paul

Paul said it was in India's interest to ensure scientific rigour is maintained while granting the licence to a vaccine

Expect AstraZeneca vaccine will be approved within days: UK NHS chief

Speaking at the FICCI's annual general meeting, David Prior said the pandemic paved way for whole new brand of research and development

Liquidations under IBC in Q2 jump, new applications remain subdued

Critics of the IBC have often pointed out that the delays in admission, resolution and liquidation might be making it an unattractive proposition